Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

doi:10.3748/wjg.v25.i11.1327

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7330)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

504

WORD

241

HTML

4342

Figures (1-5)

261

Tables (1-4)

231

Sum=5579

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

767

Download

984

Sum=1751

Mar 21, 2019 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Mar 21, 2019; 25(11): 1327-1340
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1327

Table 2 Annual direct costs per patients in Euros

	Annual costs, €
Lab costs for anti-HCV, RNA test, genotyping exam and liver biopsy/elastography	350
Screening cost per screen	10¹
Cost per diagnosed patient without antiviral treatment
F0-F3	230
Compensated cirrhosis, F4	1340
Decompensated cirrhosis	4460
Hepatocellular carcinoma	33000
Liver transplantation	134600²
Liver transplant - subsequent years	4600
Antiviral treatment costs of DAAs
2015-2016	42000
2017-2023	13000
2024-2035	13000/8500³

¹Cost per screen;

²Cost per patient for one time (includes all pre-transplantation, transplantation and post-transplantation courses);

³Under optimistic price reduction scenario. DAAs: Direct-acting antivirals; HCV: Hepatitis C virus.

Citation: Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol 2019; 25(11): 1327-1340
URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1327.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1327